Verastem, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Verastem, Inc. (VSTM) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$34.67 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-06
- Verastem, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$34.67M.
- Verastem, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$45.91M.
- Verastem, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-06-30 was -$46.25M.
- Verastem, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-03-31 was -$52.10M.
- Verastem, Inc. net income (loss) available to common stockholders, diluted for fiscal 2020 was -$67.73M.
- Verastem, Inc. net income (loss) available to common stockholders, diluted for fiscal 2019 was -$149.21M.
- Verastem, Inc. net income (loss) available to common stockholders, diluted for fiscal 2018 was -$94.92M.
- Verastem, Inc. net income (loss) available to common stockholders, diluted for fiscal 2017 was -$67.80M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|
| 2026-06-30 | -$34.67M 10-Q · filed 2026-08-06 | -$80.59M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | -$45.91M 10-Q · filed 2026-05-07 | ||
| 2025-06-30 | -$46.25M 10-Q · filed 2026-08-06 | -$95.94M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | -$52.10M 10-Q · filed 2026-05-07 | ||
| 2024-06-30 | -$8.26M 10-Q · filed 2025-08-07 | -$42.12M 10-Q · filed 2025-08-07 | |
| 2020-12-31 | -$67.73M 10-K · filed 2021-03-18 | ||
| 2019-12-31 | -$149.21M 10-K · filed 2021-03-18 | ||
| 2018-12-31 | -$94.92M 10-K · filed 2021-03-18 | ||
| 2017-12-31 | -$67.80M 10-K · filed 2020-03-11 | ||
| 2016-12-31 | -$36.44M 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |